What is the average price target for CYNGN INC (CYN) stock?
5 analysts have analysed CYN and the average price target is 5.1 USD. This implies a price increase of 203.57% is expected in the next year compared to the current price of 1.68.
NASDAQ:CYN • US23257B3050
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CYNGN INC (CYN).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2021-11-16 | Aegis Capital | Initiate | Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.489M 472.81% | 368.1K -75.28% | 219K -40.51% | 7.575M 3,358.90% | 33.896M 347.47% | |
| EBITDA YoY % growth | -22.385M -19.07% | -22.159M 1.01% | -24.498M -10.56% | -17.271M 29.50% | 7.545M 143.69% | |
| EBIT YoY % growth | -23.346M -20.34% | -22.828M 2.22% | -25.688M -12.53% | -19.089M 25.69% | 5.171M 127.09% | |
| Operating Margin | -1,567.58% | -6,201.60% | -11,729.77% | -252.00% | 15.26% | |
| EPS YoY % growth | -8,809.09 -5.90% | -2,732.53 68.98% | N/A 99.74% | -3.67 47.92% | 319.67 8,819.01% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.61 86.20% | -0.30 88.78% | -0.26 78.12% | -0.19 81.00% |
| Revenue Q2Q % growth | 404K 759.57% | 1.111M 3,193.80% | 2.222M 3,075.65% | 3.838M 5,462.32% |
| EBITDA Q2Q % growth | -4.949M 0.50% | -4.949M -1.02% | -4.343M 42.27% | -3.03M 43.52% |
| EBIT Q2Q % growth | -5.252M -0.71% | -5.252M 4.54% | -4.646M 44.80% | -3.333M 49.15% |
All data in USD
5 analysts have analysed CYN and the average price target is 5.1 USD. This implies a price increase of 203.57% is expected in the next year compared to the current price of 1.68.
CYNGN INC (CYN) will report earnings on 2026-05-05.
The consensus EPS estimate for the next earnings of CYNGN INC (CYN) is -0.61 USD and the consensus revenue estimate is 404.00K USD.
The consensus rating for CYNGN INC (CYN) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.